Sosei Group Corporation and Novartis announced results from a Phase 3 study of NVA237 (glycopyrronium bromide) for the treatment of patients with chronic obstructive pulmonary disease (COPD).  The pivotal double-blind, 26-week GLOW1 study met its primary endpoint by demonstrating superior bronchodilation to placebo at 12 weeks measured by trough FEV1 (forced expiratory volume in 1 second) (P<0.001). Results showed that NVA237 significantly improved lung function while demonstrating a good safety profile in patients with moderate-to-severe COPD.

NVA237 is a once-daily, long-acting muscarinic antagonist (LAMA) being developed to treat COPD.

For more information visit